Abstract:Gut microbiota is explicitly associated with the development of depressive disorder. However, the molecular pathogenesis associated with gut microbiota with MDD remains unclear. Shugan granule (SGKL), a Chinese patent medicine, is a potential anti‐depression drug via gut microbiota, but the molecular therapeutic mechanism of SGKL remains unknown for the depression process. Our previous study determined SGKL might contribute to alleviating depression symptoms through the PI3K/Akt/mTOR pathway. There is a lack of the investigation to demonstrate whether SGKL can target PI3K/Akt/mTOR pathway based on altered gut microbiota, leading to the improvement of depression progression. We showed a novel mechanism of gut microbiota in causing depression; gut microbiota cause changes in phosphorylation of the PI3K/Akt/mTOR pathway, which mediates microglial activation and subsequent inflammation, eventually causing the development of depression. Importantly, SGKL treatment targets the PI3K/Akt/mTOR pathway in improving depression‐like behaviour, microglia activation, and inflammation. Moreover, we concluded that Parasutterella, Aeromonas, Ruminococcaceae_UCG_008, Globiocatella, Shuttleworthia, and Clostridium_sensu_stricto_1 were the biomarkers of depression, and Candidatus Arthromitus might be the therapeutic target of SGKL during improving depressive‐like behaviours. These findings suggests that SGKL may be the reliable and rational drug for the treatment in depression. Aim The investigation aims to evaluate the potential effect of Shugan Granule (SGKL) on the gut, brain, and behaviors in rats exposed to chronic restraint stress (CRS). Methods The fecal microbiota and metabolite changes were studied in rats exposed to CRS and treated with SGKL (0.1 mg/kg/day). Depressive behaviors of these rats were determined through an open‐field experiment, forced swimming test, sucrose preference, and weighing. Moreover, LPS‐stimulated microglia and CRS‐stimulated rats were treated with SGKL to investigate the regulation between SGKL and the PI3K/Akt/pathway, which is inhibited by LY294002, a PI3K inhibitor. Results (i) SGKL improved the altered behaviors in CRS‐stimulated rats; (ii) SGKL ameliorated the CRS‐induced neuronal degeneration and tangled nerve fiber and also contributed to the recovery of intestinal barrier injury in these rats; (iii) SGKL inhibited the hippocampus elevations of TNF‐α, IL‐1β, and IL‐6 in response to CRS modeling; (iv) based on the principal coordinates analysis (PCoA), SGKL altered α‐diversity indices and shifted β‐diversity in CRS‐stimulated rats; (v) at the genus level, SGKL decreased the CRS‐enhanced abundance of Bacteroides; (vi) Butyricimonas and Candidatus Arthromitus were enriched in SGKL‐treated rats; (vii) altered gut microbiota and metabolites were correlated with behaviors, inflammation, and PI3K/Akt/mTOR pathway; (viii) SGKL increased the LPS‐decreased phosphorylation of the PI3K/Akt/mTOR pathway in microglia and inhibited the LPS‐induced microglial activation; (ix) PI3K/Akt/mTOR pathway inactivation reversed the SGKL effects in CRS rats. Conclusion SGKL targets the PI3K/Akt/mTOR pathway by altering gut microbiota and metabolites, which ameliorates altered behavior and inflammation in the hippocampus.

Investigation of the Antidepressant Effects of Shu-Gan-Jie- Yu Granule and Its Mechanism of Action

Antidepressant-Like Effects of Sanyuansan in the Mouse Forced Swim Test, Tail Suspension Test, and Chronic Mild Stress Model

Antidepressant Effect of Chronically Administrated Jieyu Decoction and Its Possible Mechanism

Geniposide exerts the antidepressant effect by affecting inflammation and glucose metabolism in a mouse model of depression

Antidepressant-like effect of the ethanolic extract from Suanzaorenhehuan Formula in mice models of depression

Antidepressant-Like Effects of GM1 Ganglioside Involving the BDNF Signaling Cascade in Mice

Analysis of Antidepressant Activity of Huang-Lian Jie-Du Decoction Through Network Pharmacology and Metabolomics

Kaixin Jieyu Granule attenuates neuroinflammation-induced depressive-like behavior through TLR4/PI3K/AKT/FOXO1 pathway: a study of network pharmacology and experimental validation

Integrating UHPLC-MS/MS quantitative analysis and exogenous purine supplementation to elucidate the antidepressant mechanism of Chaigui granules by regulating purine metabolism

Effects of Shugan Jieyuling self-made on behavior and levels of serum IL-2, IL-6 and cortisol in depression models

Role of PGC-1α Mediated Synaptic Plasticity, Mitochondrial Function, and Neuroinflammation in the Antidepressant Effect of Zi-Shui-Qing-Gan-Yin

Shugan granule contributes to the improvement of depression‐like behaviors in chronic restraint stress‐stimulated rats by altering gut microbiota

Evaluation of therapeutic markers and mechanism of Shuganjieyu capsule in treatment of depression

Clinical efficacy of Shugan granule in the treatment of mixed anxiety-depressive disorder: A multicenter, randomized, double-blind, placebo-controlled trial

Antidepressant-Like Effects of Yueju Ganmai Dazao Decoction Associated with PKA-CREB-BDNF Signaling Pathway in the Hippocampus of Mice

Combining network pharmacology and experimental verification to reveal the mechanism of Chaigui granules in the treatment of depression through PI3K/Akt/mTOR signaling pathways

Pharmacological mechanism of Shaoyao Gancao Decoction in the treatment of depression based on bioinformatics and animal experiment

A Serum Pharmacochemistry and Network Pharmacology-based Approach to Study the Anti-depressant Effect of Chaihu-Shugan San

Anxiolytic effect of YangshenDingzhi granules: Integrated network pharmacology and hippocampal metabolomics

Plasma metabolomics and network pharmacology identified glutamate, glutamine, and arginine as biomarkers of depression under Shuganjieyu capsule treatment

Effect of Shuganjieyu Capsules on Neuronal Apoptosis in Hippocampal CA3 Area and the Expression of Caspase-3 in the Brain of Rat Depression Model